QualityStocksNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Share CLEAR MIND Study Results in Featured Research Oral Presentation at 2024 AAIC
Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the company’s CLEAR MIND Phase 2a study results. A Phase 2a randomized clinical trial, CLEAR-MIND is evaluating Lomecel-B(TM) in mild Alzheimer’s disease. In addition to the study results, Longeveron has been accepted for a poster presentation at the 2024 Alzheimer’s Association International Conference (“AAIC”) taking place online and in Philadelphia, Pennsylvania, from July 28 – August 1, 2024. “We are extremely excited to share the full study results of our CLEAR-MIND trial at the…